Accuracy, Safety, and Reliability of Novel Phase I Trial Designs
暂无分享,去创建一个
[1] Alexia Iasonos,et al. A Comprehensive Comparison of the Continual Reassessment Method to the Standard 3 + 3 Dose Escalation Scheme in Phase I Dose-Finding Studies , 2008, Clinical trials.
[2] Ying Yuan,et al. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials , 2016, Clinical Cancer Research.
[3] Ying Yuan,et al. Bayesian dose finding in oncology for drug combinations by copula regression , 2009 .
[4] H. D. Brunk,et al. Statistical inference under order restrictions : the theory and application of isotonic regression , 1973 .
[5] Matthieu Clertant,et al. Semiparametric dose finding methods , 2017 .
[6] Michael Branson,et al. Critical aspects of the Bayesian approach to phase I cancer trials , 2008, Statistics in medicine.
[7] Yuan Ji,et al. A modified toxicity probability interval method for dose-finding trials. , 2010, Clinical trials.
[8] J O'Quigley,et al. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.
[9] Ying Yuan,et al. Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials , 2009 .
[10] Fangrong Yan,et al. Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials , 2017, Clinical Cancer Research.
[11] J. Lee,et al. Dose Escalation Methods in Phase I Cancer Clinical Trials , 2009, Journal of the National Cancer Institute.
[12] John O'Quigley,et al. Continual Reassessment Method for Partial Ordering , 2011, Biometrics.
[13] Y K Cheung,et al. Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities , 2000, Biometrics.
[14] Ying Yuan,et al. BAYESIAN DATA AUGMENTATION DOSE FINDING WITH CONTINUAL REASSESSMENT METHOD AND DELAYED TOXICITY. , 2013, The annals of applied statistics.
[15] Ying Yuan,et al. Comparative review of novel model‐assisted designs for phase I clinical trials , 2018, Statistics in medicine.
[16] S Zacks,et al. Cancer phase I clinical trials: efficient dose escalation with overdose control. , 1998, Statistics in medicine.
[17] B E Storer,et al. An evaluation of phase I clinical trial designs in the continuous dose–response setting , 2001, Statistics in medicine.
[18] Guosheng Yin,et al. Bayesian optimal interval design for dose finding in drug-combination trials , 2017, Statistical methods in medical research.
[19] Ying Yuan,et al. Bayesian optimal interval designs for phase I clinical trials , 2015, Journal of the Royal Statistical Society: Series C (Applied Statistics).
[20] Yuan Ji,et al. A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2. , 2016, Contemporary clinical trials.